Global risk management in patients with type 2 diabetes mellitus.
It is well established that aggressive risk factor modification results in improved cardiovascular disease (CVD) outcomes. Yet, patients with type 2 diabetes mellitus have a much higher baseline risk for cardiovascular events. As type 2 diabetes and hypertension commonly coexist, achieving recommended targets for diabetes, hypertension, and CVD requires aggressive management. Global risk reduction with aggressive low-density lipoprotein reduction and through the additional normalization of glucose levels and blood pressure can help to reduce absolute risk in this very high-risk population.
Davidson
Michael H
MH
Rush University Medical Center, Chicago, Illinois 60612, USA. michaeldavidson@radiantresearch.com
D000465:Algorithms; D001055:Apolipoproteins B / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000517:prevention & control*; D006801:Humans; D006973:Hypertension / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D010446:Peptide Fragments / Q000097:blood; D012307:Risk Factors
D001055:Apolipoproteins B; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D010446:Peptide Fragments; C093007:apolipoprotein B (3304-3317); D002097:C-Reactive Protein; D002784:Cholesterol